Journal Article

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases: TAFIa level in patients with IBD

Danuta Owczarek, Anetta Undas, Jonathan H. Foley, Michael E. Nesheim, Konrad Jabłonski and Tomasz Mach

in Journal of Crohn's and Colitis

Published on behalf of European Crohn's and Colitis Organisation

Volume 6, issue 1, pages 13-20
Published in print February 2012 | ISSN: 1873-9946
Published online February 2012 | e-ISSN: 1876-4479 | DOI: https://dx.doi.org/10.1016/j.crohns.2011.06.005
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases: TAFIa level in patients with IBD

More Like This

Show all results sharing these subjects:

  • Medicine and Health
  • Clinical Medicine
  • Gastroenterology
  • Gastro-intestinal and Colorectal Surgery
  • Health, Illness, and Medicine

GO

Show Summary Details

Preview

Abstract

Background: Thrombin activatable fibrinolysis inhibitor (TAFI) has been reported to be involved in the pathogenesis and progression of inflammatory bowel disease (IBD). Activated TAFI (TAFIa) attenuates fibrinolysis by cleaving C-terminal lysine residues thus down-regulating plasminogen activation. To date, no reports on TAFIa in IBD have been published.

Methods: Plasma levels of TAFIa were measured using a functional assay in 55 consecutive patients with ulcerative colitis (UC) and 50 with Crohn's disease (CD). Associations of TAFIa with disease activity, hemostatic variables and inflammatory markers were assessed.

Results: Plasma TAFIa was higher in CD patients than in those with UC. The disease activity correlated positively with TAFIa levels in the UC group, but not in the CD group. In UC patients, there were positive correlations of TAFIa with white blood cells, C-reactive protein and fibrinogen and an inverse correlation with albumin. In the CD group, a positive correlation was shown for C-reactive protein, fibrinogen and platelet count, while a negative correlation was noted for albumin.

Conclusions: This study is the first to show that TAFIa is increased in CD patients compared with UC and its levels are associated with inflammatory markers in both forms of IBD. These findings fit in the hypothesis that TAFIa may be a marker of active IBD, and in particular of active UC.

Highlights: ► Thrombin activatable fibrinolysis inhibitor (TAFI) has been reported to be involved in the pathogenesis and progression of inflammatory bowel disease. ► This study is the first to show that TAFIa is increased in CD patients compared with UC and its levels are associated with inflammatory markers in both forms of IBD. ► TAFIa may be considered as a marker of exacerbated UC, but not CD.

Keywords: Inflammatory bowel disease; Inflammation; TAFI; Carboxypeptidase U

Journal Article.  4276 words.  Illustrated.

Subjects: Medicine and Health ; Clinical Medicine ; Gastroenterology ; Gastro-intestinal and Colorectal Surgery ; Health, Illness, and Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.